Fuhong Hanlin: The first patient has been dosed in the Hans joint chemotherapy first-line treatment ES-SCLC Japan bridge trial.

Jin10 data reported on June 24, the company Fuhong Hanlin announced that the first patient has been dosed in the Japanese bridge trial of Hanshuo (Surlulimumab Injection) combined with chemotherapy (Carboplatin-Etoposide) as the first-line treatment for extensive stage small cell lung cancer (ES-SCLC). This trial aims to support the market authorization application for Hanshuo in Japan. Previously, an international multi-center phase III clinical trial comparing Hanshuo or placebo combined with chemotherapy as the first-line treatment for ES-SCLC reached its primary endpoint of overall survival (OS) in December 2021.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate app
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)